Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates: Preliminary studies

D. S. Tai, C. Hu, Charles C Lee, M. Martinez, G. Cantero, E. H. Kim, Alice F Tarantal, G. S. Lipshutz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Achieving persistent expression is a prerequisite for effective genetic therapies for inherited disorders. These proof-of-concept studies focused on adeno-associated virus (AAV) administration to newborn monkeys. Serotype rh10 AAV expressing ovalbumin and green fluorescent protein (GFP) was administered intravenously at birth and compared with vehicle controls. At 4 months postnatal age, a second injection was administered intramuscularly, followed by vaccination at 1 year of age with ovalbumin and GFP. Ovalbumin was highest 2 weeks post administration in the treated monkey, which declined but remained detectable thereafter; controls demonstrated no expression. Long-term AAV genome copies were present in myocytes. At 4 weeks, neutralizing antibodies to rh10 were present in the experimental animal only. With AAV9 administration at 4 months, controls showed transient ovalbumin expression that disappeared with the development of strong anti-ovalbumin and anti-GFP antibodies. In contrast, increased and maintained ovalbumin expression was noted in the monkey administered AAV at birth, without antibody development. After vaccination, the experimental monkey maintained levels of ovalbumin without antibodies, whereas controls demonstrated high levels of antibodies. These preliminary studies suggest that newborn AAV administration expressing secreted and intracellular xenogenic proteins may result in persistent expression in muscle, and subsequent vector administration can result in augmented expression without humoral immune responses.

Original languageEnglish (US)
Pages (from-to)923-930
Number of pages8
JournalGene Therapy
Volume22
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Ovalbumin
Primates
Dependovirus
Haplorhini
Genes
Green Fluorescent Proteins
Antibodies
Vaccination
Parturition
Humoral Immunity
Neutralizing Antibodies
Genetic Therapy
Muscle Cells
Genome
Muscles
Injections
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates : Preliminary studies. / Tai, D. S.; Hu, C.; Lee, Charles C; Martinez, M.; Cantero, G.; Kim, E. H.; Tarantal, Alice F; Lipshutz, G. S.

In: Gene Therapy, Vol. 22, No. 11, 01.11.2015, p. 923-930.

Research output: Contribution to journalArticle

Tai, D. S. ; Hu, C. ; Lee, Charles C ; Martinez, M. ; Cantero, G. ; Kim, E. H. ; Tarantal, Alice F ; Lipshutz, G. S. / Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates : Preliminary studies. In: Gene Therapy. 2015 ; Vol. 22, No. 11. pp. 923-930.
@article{40499e7817ac4ab1b750acd5b1fe4e5e,
title = "Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates: Preliminary studies",
abstract = "Achieving persistent expression is a prerequisite for effective genetic therapies for inherited disorders. These proof-of-concept studies focused on adeno-associated virus (AAV) administration to newborn monkeys. Serotype rh10 AAV expressing ovalbumin and green fluorescent protein (GFP) was administered intravenously at birth and compared with vehicle controls. At 4 months postnatal age, a second injection was administered intramuscularly, followed by vaccination at 1 year of age with ovalbumin and GFP. Ovalbumin was highest 2 weeks post administration in the treated monkey, which declined but remained detectable thereafter; controls demonstrated no expression. Long-term AAV genome copies were present in myocytes. At 4 weeks, neutralizing antibodies to rh10 were present in the experimental animal only. With AAV9 administration at 4 months, controls showed transient ovalbumin expression that disappeared with the development of strong anti-ovalbumin and anti-GFP antibodies. In contrast, increased and maintained ovalbumin expression was noted in the monkey administered AAV at birth, without antibody development. After vaccination, the experimental monkey maintained levels of ovalbumin without antibodies, whereas controls demonstrated high levels of antibodies. These preliminary studies suggest that newborn AAV administration expressing secreted and intracellular xenogenic proteins may result in persistent expression in muscle, and subsequent vector administration can result in augmented expression without humoral immune responses.",
author = "Tai, {D. S.} and C. Hu and Lee, {Charles C} and M. Martinez and G. Cantero and Kim, {E. H.} and Tarantal, {Alice F} and Lipshutz, {G. S.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1038/gt.2015.65",
language = "English (US)",
volume = "22",
pages = "923--930",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates

T2 - Preliminary studies

AU - Tai, D. S.

AU - Hu, C.

AU - Lee, Charles C

AU - Martinez, M.

AU - Cantero, G.

AU - Kim, E. H.

AU - Tarantal, Alice F

AU - Lipshutz, G. S.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Achieving persistent expression is a prerequisite for effective genetic therapies for inherited disorders. These proof-of-concept studies focused on adeno-associated virus (AAV) administration to newborn monkeys. Serotype rh10 AAV expressing ovalbumin and green fluorescent protein (GFP) was administered intravenously at birth and compared with vehicle controls. At 4 months postnatal age, a second injection was administered intramuscularly, followed by vaccination at 1 year of age with ovalbumin and GFP. Ovalbumin was highest 2 weeks post administration in the treated monkey, which declined but remained detectable thereafter; controls demonstrated no expression. Long-term AAV genome copies were present in myocytes. At 4 weeks, neutralizing antibodies to rh10 were present in the experimental animal only. With AAV9 administration at 4 months, controls showed transient ovalbumin expression that disappeared with the development of strong anti-ovalbumin and anti-GFP antibodies. In contrast, increased and maintained ovalbumin expression was noted in the monkey administered AAV at birth, without antibody development. After vaccination, the experimental monkey maintained levels of ovalbumin without antibodies, whereas controls demonstrated high levels of antibodies. These preliminary studies suggest that newborn AAV administration expressing secreted and intracellular xenogenic proteins may result in persistent expression in muscle, and subsequent vector administration can result in augmented expression without humoral immune responses.

AB - Achieving persistent expression is a prerequisite for effective genetic therapies for inherited disorders. These proof-of-concept studies focused on adeno-associated virus (AAV) administration to newborn monkeys. Serotype rh10 AAV expressing ovalbumin and green fluorescent protein (GFP) was administered intravenously at birth and compared with vehicle controls. At 4 months postnatal age, a second injection was administered intramuscularly, followed by vaccination at 1 year of age with ovalbumin and GFP. Ovalbumin was highest 2 weeks post administration in the treated monkey, which declined but remained detectable thereafter; controls demonstrated no expression. Long-term AAV genome copies were present in myocytes. At 4 weeks, neutralizing antibodies to rh10 were present in the experimental animal only. With AAV9 administration at 4 months, controls showed transient ovalbumin expression that disappeared with the development of strong anti-ovalbumin and anti-GFP antibodies. In contrast, increased and maintained ovalbumin expression was noted in the monkey administered AAV at birth, without antibody development. After vaccination, the experimental monkey maintained levels of ovalbumin without antibodies, whereas controls demonstrated high levels of antibodies. These preliminary studies suggest that newborn AAV administration expressing secreted and intracellular xenogenic proteins may result in persistent expression in muscle, and subsequent vector administration can result in augmented expression without humoral immune responses.

UR - http://www.scopus.com/inward/record.url?scp=84947031699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947031699&partnerID=8YFLogxK

U2 - 10.1038/gt.2015.65

DO - 10.1038/gt.2015.65

M3 - Article

C2 - 26333349

AN - SCOPUS:84947031699

VL - 22

SP - 923

EP - 930

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 11

ER -